6943-33-5

Usage

Uses

Used in Organic Synthesis:
5-(3-BROMO-PHENYL)-5-METHYL-IMIDAZOLIDINE-2,4-DIONE is used as a building block in organic synthesis for the creation of various chemical compounds. Its unique structure allows for versatile reactions and the formation of a wide range of derivatives, contributing to the advancement of chemical research and development.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 5-(3-BROMO-PHENYL)-5-METHYL-IMIDAZOLIDINE-2,4-DIONE is utilized as a starting material for the synthesis of pharmaceutical compounds. Its potential pharmacological properties make it a promising candidate for the development of new drugs, particularly those targeting specific biological pathways or diseases.
Used in Pharmaceutical Industry:
5-(3-BROMO-PHENYL)-5-METHYL-IMIDAZOLIDINE-2,4-DIONE is used as a precursor in the pharmaceutical industry for the synthesis of biologically active molecules. Its heterocyclic nature and functional groups provide opportunities for the design and synthesis of novel therapeutic agents with improved efficacy and selectivity.
Used in Research and Development:
5-(3-BROMO-PHENYL)-5-METHYL-IMIDAZOLIDINE-2,4-DIONE is employed in research and development settings to explore its chemical reactivity, stability, and potential applications in various scientific and technological fields. Its unique properties make it an interesting subject for further investigation and innovation.

InChI:InChI=1/C10H9BrN2O2/c1-10(8(14)12-9(15)13-10)6-3-2-4-7(11)5-6/h2-5H,1H3,(H2,12,13,14,15)

Upstream product

• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 506-87-6 ammonium carbonate 
• 151-50-8 potassium cyanide 

Downstream Products

• 1262858-65-0 (RS)-2-amino-2-(3-bromo-phenyl)-propionic acid hydrochloride 
• 1372806-23-9 C₁₁H₁₁BrN₂OS 
• 856877-35-5 C₁₁H₁₂BrN₃O 
• 856884-79-2 C₁₇H₁₆ClN₃O 
• 1372806-08-0 C₁₁H₁₁BrN₂O₂ 
• 1183013-69-5 (RS)-2-amino-2-(3-bromo-phenyl)-propan-1-ol 
• 1262858-67-2 rac-5-(3-bromophenyl)-5-methylmorpholin-3-one 
• 1262858-69-4 rac-5-(3-bromophenyl)-5-methyl-5,6-dihydro-2H-[1,4]oxazin-3-ylamine 
• 1183581-39-6 (RS)-2-amino-2-(3-bromo-phenyl)-propionic acid methyl ester 
• 1266784-81-9 (RS)-3-(3-Bromo-phenyl)-5-methoxy-3-methyl-3,6-dihydro-2H [1,4]oxazine 
• 1266784-96-6 (RS)-[bis-(4-methoxy-phenyl)-phenyl-methyl]-[5-(3-bromo-phenyl)-5-methyl-5,6-dihydro-2H-[1,4]oxazin-3-yl]-amine 
• 1386997-98-3 (RS)-(3-chloro-benzyl)-[3-(5-methoxy-3-methyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-phenyl]-amine 
• 1071454-35-7 5-{3-[3-(2-methoxy-phenyl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-phenyl}-5-methyl-imidazolidine-2,4-dione 
• 916770-75-7 3-[4-(3-bromo-phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-ylmethyl]-benzoic acid methyl ester 

Relevant academic research and scientific papers

Identification and Profiling of Hydantoins - A Novel Class of Potent Antimycobacterial DprE1 Inhibitors

Tuberculosis is the leading cause of death worldwide from infectious diseases. With the development of drug-resistant strains of Mycobacterium tuberculosis, there is an acute need for new medicines with novel modes of action. Herein, we report the discovery and profiling of a novel hydantoin-based family of antimycobacterial inhibitors of the decaprenylphospho-β-d-ribofuranose 2-oxidase (DprE1). In this study, we have prepared a library of more than a 100 compounds and evaluated them for their biological and physicochemical properties. The series is characterized by high enzymatic and whole-cell activity, low cytotoxicity, and a good overall physicochemical profile. In addition, we show that the series acts via reversible inhibition of the DprE1 enzyme. Overall, the novel compound family forms an attractive base for progression to further stages of optimization and may provide a promising drug candidate in the future.

5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES

The present invention provides a compound of formula I' having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are

5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS

The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention relates to 1,4 Oxazines of formula (I): having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pre

Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor

From an initial lead 1, a structure-based design approach led to identification of a novel, high-affinity iminohydantoin BACE1 inhibitor that lowers CNS-derived Aβ following oral administration to rats. Herein we report SAR development in the S3 and F′ subsites of BACE1 for this series, the synthetic approaches employed in this effort, and in vivo data for the optimized compound.

1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention relates to 1,4 Oxazines of formula I having BACE 1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the prese

1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention provides 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present

3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES

The present invention relates to 3-Amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. T

3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES

The present invention relates to 3-Amino-5-phenyl-5,6-dihydro-2H-[l,4]oxazine derivatives of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active

Macrocyclic heterocyclic aspartyl protease inhibitors

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt, solvate or ester thereof, wherein U, W, X, L, Y, M, Z, c, d, e, f, g, h, s, t, R1, R2, R7, R8, R9/